PMID-15612551 – Prostamax Effect on Heterochromatin of Human Lymphocytes
Khavinson VKh, Lezhava TA, Monaselidze JR, et al. [The influence of the peptide bioregulator prostamax on heterochromatin of human lymphocytes in situ]. Tsitologiia. 2004;46(10):865-870.
Quick Reference
| Property | Value |
|---|---|
| PMID | 15612551 |
| DOI | — |
| Year | 2004 |
| Journal | Tsitologiia (Cytology) |
| Study Type | In vitro |
| Evidence Level | V |
| Sample | Cultured human lymphocytes |
| Peptide(s) Studied | Prostamax |
Key Findings
- Prostamax (Lys-Glu-Asp-Pro) induced changes in heterochromatin structure of human lymphocytes in situ
- The peptide caused partial decondensation of heterochromatic regions, consistent with the Khavinson epigenetic bioregulation model
- The chromatin remodeling effect was observed at concentrations used in standard bioregulator protocols
- Results are analogous to those obtained with other Khavinson peptides (Vilon, Livagen) in similar chromatin assays
Study Design
In vitro cytogenetic study using cultured human lymphocytes. Cells were treated with Prostamax and heterochromatin was assessed using differential staining techniques to quantify condensation state changes.
Limitations
- In vitro study only; lymphocytes are not the target tissue (prostate) for Prostamax
- Published in Russian-language journal (Tsitologiia)
- Very limited sample
- Chromatin changes in lymphocytes do not prove prostate-specific activity
- All authors from the Khavinson group
- No independent replication
Clinical Relevance
The chromatin remodeling data is consistent with the broader Khavinson bioregulation theory but does not provide direct evidence for prostate-specific therapeutic effects. No clinical data exists for Prostamax in BPH or other prostatic conditions.
Methodological Note: This study originates from the Khavinson bioregulation group. Independent replication by Western laboratories is lacking.
Related
#research #in-vitro #evidence-level-V #khavinson-bioregulator #peptide-prostamax